Daily Aspirin Use Associated With Reduced Risk for Fibrosis Progression in Patients With Nonalcoholic Fatty Liver Disease

Simon et  al1 recently published a report in Clinical Gastroenterology and Hepatology on their findings from a prospective cohort study of 361 adults with biopsy-confirmed nonalcholic fatty liver disease (NAFLD). Their study evaluated the relationship between daily aspirin use and risk for fibrosis progress ion defined by using serial measurements of validated indices (the Fibrosis-4, NAFLD fibrosis score, and aspartate aminotransferase-to-platelet ratio indices). They concluded that daily aspirin use was associated with less severe histologic features of NAFLD and nonalcoholic steatohepatitis and lowe r risk for progression to advanced fibrosis with time.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research